| Trial ID: | L4736 |
| Source ID: | NCT01354990
|
| Associated Drug: |
Sitagliptin (Januvia®)
|
| Title: |
A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01354990/results
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Sitagliptin (JANUVIA®)
|
| Outcome Measures: |
Primary: Number of Participants With an Adverse Event, Up to approximately 28 months|Age of Participants Prescribed Sitagliptin, Up to approximately 28 months|Number of Participants With Concomitant Therapies, Up to approximately 28 months|Number of Participants With Concomitant Conditions, Up to approximately 28 months |
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
2974
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2009-02
|
| Completion Date: |
2010-05
|
| Results First Posted: |
2012-06-04
|
| Last Update Posted: |
2015-08-27
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT01354990
|
